Cefixime Trihydrate is an oral third generation cephalosporin antibiotic used to treat infections caused by bacteria such as pneumonia; bronchitis; gonorrhea; and ear, lung, throat, and urinary tract infections.Cefixime is used to treat many different types of infections caused by bacteria. Cefixime may also be used for other purposes not listed in this medication guide.
Ofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.
Indications and Usage
- Typhoid Fever
- Urinary Tract Infection
- Respiratory Tract Infection
- Nosocomial Infections
- Soft Tissue Infections
- Surgical Prophylaxis
- Intra-abdominal Infections.
Rationale of Combination
● Unique Dual Mode Of Action
● Ofloxacin-Prevents nucleic acid synthesis
● Cefixime-Inhibits cell wall synthesis
● Acts synergetically
● Gives better patient compliance.
Cefixime Trihydrate:Absorption: About 40% to 50% is absorbed. C maxfollowing 200 and 400 mg doses of oral suspension are 3 and 4.6 mcg/mL, respectively. T max occurs between 2 and 6 h following administration of 400 mg and between 2 and 5 h after a 200 mg dose.
Distribution: Protein binding is about 65%. Elimination: About 50% of absorbed dose is excreted unchanged in the urine in 24 h. Serum t ½averages 3 to 4 h, but may be as long as 9 h in some healthy subjects.
Ofloxacin:Absorption: Following oral administration, the bioavailability of ofloxacin in the tablet formulation is approximately 98%. Maximum serum concentrations are achieved one to two hours after an oral dose.
Half Life: 9 hours.
Elimination: Elimination is mainly by renal excretion. Between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. Four to eight percent of an ofloxacin dose is excreted in the feces. This indicates a small degree of biliary excretion of ofloxacin.
Mechanism of Action
Adverse Drug Reaction
● Adequate hydration of patients receiving ofloxacin should be maintained to prevent the formation of highly concentrated urine.
● Administer ofloxacin with caution in the presence of renel or heptic impairment. In patients with known or suspected renel or heptic impairment, careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of ofloxacin may be reduced.
● The possibility of the emergence of resistant organisms which might result in overgrowth should be kept in mind, particularly during prolonged treatment. In such use, careful observation of the patient is essential. If super infection occurs during therapy, appropriate measures should be taken. The dose of cefixime should be adjusted in patients with renel impairment as well as those undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD).
● Patient on dialysis should be monitored carefully. Cefixime should be prescribed with caution In individuals with a history of gastrointestinal disease, particularly colitis.